These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 1704264

  • 21. Sensitive antiproliferative neutralization assay for the detection of neutralizing IFN-alpha and IFN-beta antibodies.
    Prümmer O, Streichan U, Heimpel H, Porzsolt F.
    J Immunol Methods; 1994 May 02; 171(1):45-53. PubMed ID: 8176238
    [Abstract] [Full Text] [Related]

  • 22. Effect of interferon-alpha on the expression and release of the CD23 molecule in hairy cell leukemia.
    Genot E, Sarfati M, Sigaux F, Petit-Koskas E, Billard C, Mathiot C, Falcoff E, Delespesse G, Kolb JP.
    Blood; 1989 Nov 15; 74(7):2455-63. PubMed ID: 2529929
    [Abstract] [Full Text] [Related]

  • 23. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
    Goldstein D, Sielaff KM, Storer BE, Brown RR, Datta SP, Witt PL, Teitelbaum AP, Smalley RV, Borden EC.
    J Natl Cancer Inst; 1989 Jul 19; 81(14):1061-8. PubMed ID: 2472488
    [Abstract] [Full Text] [Related]

  • 24. Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia.
    Huber C, Aulitzky W, Tilg H, von Lüttichau I, Troppmair J, Nachbauer K, Gastl G.
    Leukemia; 1987 Apr 19; 1(4):355-7. PubMed ID: 3669762
    [Abstract] [Full Text] [Related]

  • 25. Reduced hematologic response to alpha-interferon therapy in patients with hairy cell leukemia showing a peculiar immunologic phenotype.
    Lauria F, Raspadori D, Foa R, Zinzani PL, Buzzi M, Gugliotta L, Macchi S, Tura S.
    Cancer; 1990 May 15; 65(10):2233-6. PubMed ID: 1693308
    [Abstract] [Full Text] [Related]

  • 26. Interferon alpha-2 for hairy cell leukemia: evidence for induction of RNA synthesis in hairy cells and failure to correlate enhancement of natural killer cells with elimination of hairy cells.
    Schwarzmeier JD, Schwabe M, Prischl F, Wagner L, Lion T, Micksche M, Köller U.
    Eur J Haematol; 1987 Nov 15; 39(5):418-25. PubMed ID: 3691760
    [Abstract] [Full Text] [Related]

  • 27. In vivo and in vitro induction of (2'-5') oligoadenylate synthetase by human interferons in leukocytes from healthy donors and patients with renal cancer and hairy cell leukemia.
    Ferbus D, Billard C, Sigaux F, Thang MN, Falcoff E.
    J Biol Regul Homeost Agents; 1987 Nov 15; 1(3):147-53. PubMed ID: 2459906
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser.
    Larocca AP, Leung SC, Marcus SG, Colby CB, Borden EC.
    J Interferon Res; 1989 Sep 15; 9 Suppl 1():S51-60. PubMed ID: 2809278
    [Abstract] [Full Text] [Related]

  • 29. Recombinant interferon alpha-C for advanced hairy cell leukemia. An Israeli multicenter study.
    Aderka D, Michalevicz R, Daniel Y, Levo Y, Douer D, Ben-Bassat I, Ramot B, Shaklai M, Prokocimer M, Berrebi A.
    Cancer; 1988 Jun 01; 61(11):2207-13. PubMed ID: 3365651
    [Abstract] [Full Text] [Related]

  • 30. The alpha interferons: clinical overview.
    Spiegel RJ.
    Semin Oncol; 1987 Jun 01; 14(2 Suppl 2):1-12. PubMed ID: 3296210
    [Abstract] [Full Text] [Related]

  • 31. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia.
    Urba WJ, Baseler MW, Kopp WC, Steis RG, Clark JW, Smith JW, Coggin DL, Longo DL.
    Blood; 1989 Jan 01; 73(1):38-46. PubMed ID: 2783373
    [Abstract] [Full Text] [Related]

  • 32. Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
    Ho AD, Thaler J, Mandelli F, Lauria F, Zittoun R, Willemze R, McVie G, Marmont AM, Prümmer O, Stryckmans P.
    J Clin Oncol; 1989 Oct 01; 7(10):1533-8. PubMed ID: 2789273
    [Abstract] [Full Text] [Related]

  • 33. [Recombinant (IFN-alpha 2b) therapy in hairy cell leukemia].
    Schwarzmeier JD, Wagner L, Prischl F, Schwabe M, Lion T, Micksche M, Köller U, Bernhart M, Fritz O, Seewann HL.
    Klin Wochenschr; 1987 Jul 15; 65(14):699-705. PubMed ID: 3114550
    [Abstract] [Full Text] [Related]

  • 34. Should alpha interferon be used as primary treatment for hairy cell leukemia? Italian Cooperative Group for Hairy Cell Leukemia.
    Capnist G, Federico M, Chisesi T, Resegotti L, Pagnucco G, Castoldi GL, Lamparelli T, Frassoldati A, Guarnaccia C, Leoni P.
    Leuk Res; 1991 Jul 15; 15(6):419-26. PubMed ID: 1861528
    [Abstract] [Full Text] [Related]

  • 35. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
    Wussow PV, Jakschies D, Freund M, Hehlmann R, Brockhaus F, Hochkeppel H, Horisberger M, Deicher H.
    Br J Haematol; 1991 Jun 15; 78(2):210-6. PubMed ID: 2064959
    [Abstract] [Full Text] [Related]

  • 36. Treatment of hairy cell leukemia with granulocyte colony-stimulating factor and recombinant consensus interferon or recombinant interferon-alpha-2b.
    Glaspy JA, Souza L, Scates S, Narachi M, Blatt L, Ambersley J, Golde DW.
    J Immunother (1991); 1992 Apr 15; 11(3):198-208. PubMed ID: 1381218
    [Abstract] [Full Text] [Related]

  • 37. Low incidence of neutralizing antibody formation to interferon-alpha 2b in human recipients.
    Dianzani F, Antonelli G, Amicucci P, Cefaro A, Pintus C.
    J Interferon Res; 1989 Sep 15; 9 Suppl 1():S33-6. PubMed ID: 2681442
    [Abstract] [Full Text] [Related]

  • 38. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
    Oberg K, Alm GV.
    J Interferon Res; 1989 Sep 15; 9 Suppl 1():S45-9. PubMed ID: 2809277
    [Abstract] [Full Text] [Related]

  • 39. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
    Schiller JH, Storer B, Paulnock DM, Brown RR, Datta SP, Witt PL, Borden EC.
    J Clin Invest; 1990 Oct 15; 86(4):1211-21. PubMed ID: 2120284
    [Abstract] [Full Text] [Related]

  • 40. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group.
    Prümmer O.
    Cancer; 1993 Mar 01; 71(5):1828-34. PubMed ID: 8448744
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.